1. Home
  2. TY vs IMCR Comparison

TY vs IMCR Comparison

Compare TY & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tri Continental Corporation

TY

Tri Continental Corporation

N/A

Current Price

$35.32

Market Cap

1.9B

Sector

Finance

ML Signal

N/A

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

N/A

Current Price

$36.86

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TY
IMCR
Founded
1929
2008
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.8B
IPO Year
1994
2016

Fundamental Metrics

Financial Performance
Metric
TY
IMCR
Price
$35.32
$36.86
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
$66.33
AVG Volume (30 Days)
27.0K
390.2K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
3.36%
N/A
EPS Growth
N/A
30.39
EPS
N/A
0.23
Revenue
N/A
$249,428,000.00
Revenue This Year
N/A
$14.57
Revenue Next Year
N/A
$8.21
P/E Ratio
$7.50
$157.91
Revenue Growth
N/A
43.05
52 Week Low
$30.53
$27.56
52 Week High
$36.55
$40.71

Technical Indicators

Market Signals
Indicator
TY
IMCR
Relative Strength Index (RSI) 47.38 61.32
Support Level $34.19 $35.46
Resistance Level $35.85 $37.38
Average True Range (ATR) 0.57 1.15
MACD -0.05 -0.00
Stochastic Oscillator 23.55 83.19

Price Performance

Historical Comparison
TY
IMCR

About TY Tri Continental Corporation

Tri-Continental Corp is a closed-end management investment company. It invests to produce future growth of both capital and income while providing reasonable current income. The fund is divided into two equal segments namely, the equity segment uses quantitative models to select individual stocks whereas the Flexible capital income segment invests across a company's investable capital structure, including stocks, bonds, and convertible securities. The Fund invests in a range of sectors, which include consumer discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, industrials, materials, real estate, telecommunication services, utilities, aerospace and defense, banking, chemicals, and others.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: